Cogent Biosciences (COGT) Preferred Stock Liabilities (2017 - 2021)

Cogent Biosciences (COGT) has 4 years of Preferred Stock Liabilities data on file, last reported at $85.4 million in Q3 2021.

• On a quarterly basis, Preferred Stock Liabilities fell 38.22% year-over-year to $85.4 million in Q3 2021; TTM through Sep 2021 was $85.4 million, a 38.22% decrease from a year earlier, with the FY2020 full-year figure at $110.9 million, changed N/A from the prior year.
• Preferred Stock Liabilities for Q3 2021 stood at $85.4 million, roughly flat from $85.4 million in the prior quarter.
• Over the last five years, Preferred Stock Liabilities for COGT reached as high as $138.2 million in Q3 2020 and fell as low as $77.2 million in Q4 2017.
• Historically, Preferred Stock Liabilities has averaged $95.6 million across 4 years, with a median of $85.4 million in 2021.
• On a YoY basis, Preferred Stock Liabilities climbed as much as 38.22% in 2021 and fell as far as 38.22% in 2021.
• Year by year, Preferred Stock Liabilities stood at $77.2 million in 2017, then increased by 0.02% to $77.2 million in 2018, then jumped by 43.69% to $110.9 million in 2020, then decreased by 22.98% to $85.4 million in 2021.
• Per Business Quant data, the three most recent Preferred Stock Liabilities figures were $85.4 million in Q3 2021, $85.4 million in Q2 2021, and $94.7 million in Q1 2021.